Combined RAAS and NEP Inhibition

Giuseppe Vergaro¹, Marco Metra²

1. Fondazione Toscana Gabriele Monasterio, Pisa, Italy
2. Professor of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Spedali Civili, Brescia Italy

Corresponding author:
Marco Metra, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Spedali Civili, Brescia Italy.
Email: metramarco@libero.it

Abstract

The neurohormonal model of HF has provided the rationale for the use of drug classes blocking the effectors of both the RAAS and SNS at different sites, including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA), and beta-blockers. Combined NEP and ACE blockade although unsuccessful with omapatrilat in the OVERTURE trial, found success with sacubitril/valsartan in the Paradigm-HF trial. The results of PARADIGM-HF trial represent one of the most significant breakthroughs in the management of HF of the last decade, representing a shift from neurohormonal antagonism to neurohormonal modulation.

Keywords: heart failure; sacubitril/valsartan; neurohormonal antagonists

Citation: Vergaro G and Metra M. Combined RAAS and NEP Inhibition. International Cardiovascular Forum Journal 2019;17:29-33, DOI: 10.17987/icfj.v17i0.601

Introduction

Neurohormonal activation in heart failure

After the pivotal observations by Cohn et al. concerning the significance of increased circulating concentrations of neurohormonal markers norepinephrine, plasma renin activity, and arginine vasopressin in patients with congestive heart failure (HF)[1], the neurohormonal model has become the main interpretative framework of the pathophysiology of HF in the last three decades.[2] Activation of neuroendocrine systems (the renin-angiotensin-aldosterone system – RAAS – and the sympathetic nervous system – SNS) after an initial insult to the cardiovascular system initially plays a compensatory role to maintain circulatory homeostasis, by supporting cardiac output and promoting peripheral vasoconstriction. Prolonged overactivation of such axes over time, however, causes maladaptive cardiac remodelling and myocardial injury, thereby initiating a vicious cycle finally which can lead to the development of the overt HF syndrome.[3]

The effects of RAAS and SNS activation are only partly counterbalanced by the natriuretic peptide (NP) system, mainly involving atrial and B-type NP (ANP and BNP, respectively). These NPs confer natriuretic, diuretic, vasodilative, anti-fibrotic and anti-hypertrophic actions, mediated through interaction with NP receptors A (NPR-A) and B (NPR-B), and via an increase in the second messenger cGMP.[4] Whilst ANP is largely produced by atrial tissue, BNP is synthesized and released by ventricular myocytes from its precursor proBNP. Upon release into the circulation, proBNP is cleaved in equal proportions into the biologically active 32 amino acid BNP, and into the biologically inactive 76 amino acid N-terminal fragment (NT-proBNP). BNP is cleared from the plasma by binding to NP receptor type C (NPR-C), and through proteolysis by neutral endopeptidase (neprilysin, NEP). In contrast, NT-proBNP is mainly cleared by renal excretion[5] and is not a substrate for NEP. NEP is a highly non-specific enzyme, exerting hydrolytic effects on several vasoactive peptides other than BNP, including substance P and bradykinin (both with vasodilative actions) and endothelin-1 and angiotensin I and II (with vasoconstrictor effects).[6,7]

The neurohormonal model of HF has provided the rationale for the use of drug classes blocking the effectors of both the RAAS and SNS at different sites, including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA), and beta-blockers. Each of these classes has provided prognostic benefit in terms of mortality and hospitalization reduction in HFpEF and related syndromes, in many cases additional to that achieved by the other classes, the exception being additional ARB on top of ACE inhibition.[8] Despite major advances in HF management, morbidity and mortality remains high, and neurohormonal antagonism incomplete, due to breakthrough phenomena.[9-11] Furthermore, until relatively recently, the therapeutic approach to HF has been restricted to the blunting of the “bad arm” of neurohormonal activation (mainly represented by RAAS and SNS over-activation), whilst no pharmacological agent was available to potentiate the “good arm”, represented by the NP system.

ISSN: 2410-2636

© 2019 Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution CC-BY-4.0 license CC-BY-4.0 (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction, provided the original work is properly cited. Published by Barcaray (International) Publishing.

* Corresponding author. E-mail: metramarco@libero.it
This may have restricted our ability fully to restore normal neurohormonal balance.

**Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers**

Activation of RAAS plays a crucial role in the pathophysiology and clinical presentation of HF. It can be a consequence of renal hypoperfusion, where a decrease in filtered sodium reaching the macula densa in the distal tubule results in an increased sympathetic stimulation of the kidney, leading to the renin release from the juxtaglomerular apparatus. Renin cleaves circulating angiotensinogen to angiotensin I, which is then converted by angiotensin converting enzyme (ACE) to the biologically active octapeptide angiotensin II. Finally, angiotensin II stimulates aldosterone production in the adrenal glands. The integrated RAAS acts both in the bloodstream in a classical endocrine mode, and within tissues in paracrine and autocrine modes.[12]

After the development of the first clinically available orally active ACE-I, captopril, which was shown to reduce mortality in patients with left ventricular (LV) systolic dysfunction following acute myocardial infarction,[13] a number of other ACE-Is have been tested in randomized clinical trials and have been demonstrated the ability to attenuate ventricular remodelling, to increase ventricular function, and to improve mortality and morbidity in patients with HFrEF.[14]

As most detrimental effects of angiotensin II are mediated by its type 1 receptor, oral ARBs were later developed for clinical use in HF, the first of them being losartan. Unlike ACEIs, ARBs do not inhibit the degradation of kinins, and are therefore less frequently associated with angioedema and cough, which are more common in patients receiving ACE-I. A summary of existing evidence on the effects of ACE-Is and ARBs in patients with HF and LV dysfunction is presented in Table 1.

According to the latest European Society of Cardiology (ESC) guidelines, ACEIs (captopril, enalapril, lisinopril, trandolapril and ramipril) are recommended, in addition to a beta-blocker, in symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death (Class I, level of evidence A), as well as in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction to prevent or delay the onset of HF and prolong life (Class I, level of evidence A) and in patients with asymptomatic LV systolic dysfunction without a history of myocardial infarction to prevent or delay the onset of HF (Class I, level of evidence B).[15]

As the evidence supporting the clinical benefit of ARBs in HF is less strong than for ACE-Is, their use (candesartan, valsartan and losartan) should be limited to HFrEF patients who are not able to tolerate an ACE-I because of serious side-effects (Class I, level of evidence B).[15]

Although there is potential for synergism between dual RAAS blockade, the ARB valsartan did not reduce mortality (while it decreased hospitalization for HF) in patients with HFpEF receiving background ACE inhibition.[16] As safety concerns were also raised, the combination of ACEIs and ARBs should be restricted to a highly selected subset of patients in whom other therapeutic options are not feasible (e.g. intolerance to MRA).[15]

**Sacubitril/valsartan: from neurohormonal antagonism to modulation**

**Nepriyslin as a therapeutic target**

The net biological effect of NEP is the sum of the inhibitory actions on systems with either vasodilative and vasoconstrictor properties. Therefore, while NEP inhibition should increase circulating NP levels, the corresponding increase in angiotensin II and endothelin-1 may mitigate NP-induced natriuresis, diuresis, anti-fibrotic and anti-hypertrophic effects. Isolated pharmacological NEP inhibition has thus never reached clinical use as a valuable option in the treatment of cardiovascular diseases.[17,18]

Combined NEP and ACE blockade was attempted by means of pharmacological agents with double inhibitory properties, the most widely tested of them being omapatrilat. In the OVERTURE trial, omapatrilat reduced the risk of cardiovascular death and of readmission for HF by approximately 10% compared to enalapril.[19] However, omapatrilat was associated with an increase in clinically relevant episodes of angioedema, likely due to the increase in circulating bradykinin levels following the combined inhibition of ACE and NEP, both acting as major enzymatic pathways of bradykinin degradation.[20]

Following these clinical and pathophysiological consideration, interest has shifted to the development of a combined NEP and angiotensin II receptor type 1 (AT1) inhibitor. The main advantage of such a strategy, further to a minor influence on bradykinin concentration, is due to the inhibition of the effects of angiotensin II generated through ACE-independent pathways and to a selective action on AT1, leaving unaffected the interaction of angiotensin II with AT2 receptor (associated to vasodilatation and improvement in cardiac and vascular function).[21-23]

**Clinical pharmacology of sacubitril/valsartan**

Sacubitril/valsartan is the first in class of angiotensin receptor/ nepriyslin inhibitors (ARNI), providing simultaneous inhibition of NEP and of RAAS. Sacubitril/valsartan (also known as LCZ696) is a novel single molecule comprising molecular moieties (in 1:1 ratio) of AHU377 (sacubitril), a prodrug which is further metabolized in the liver to LBQ657 (sacubitrilat), the biologically active NEP inhibitor, and valsartan, an AT1 receptor antagonist.[24-26] With the use of sacubitril/valsartan a blockade of angiotensin II is achieved, and, at the same time, a decrease in the breakdown of endogenous NP potentiates their vasodilative, natriuretic, diuretic and anti-remodelling effects, as supported by the increase in plasma cGMP[27] (Figure 6.1). Moreover, while omapatrilat is a blocker of three main enzymes involved in bradykinin degradation (ACE, APP and NEP), sacubitril/valsartan only inhibits one (NEP). The half-lives of LBQ657 and valsartan are similar at 12 hours and 14 hours, respectively, allowing for twice daily administration. Bioavailability is around 60% and 25% for sacubitril and valsartan respectively. Specifically, the valsartan moiety in sacubitril/valsartan appears to be significantly more bioavailable than what would be expected by equimolar amount of valsartan as an individual drug.[28]

**Sacubitril/valsartan in heart failure with reduced ejection fraction: the PARADIGM-HF trial**

The PARADIGM (Prospective Comparison of ARNI with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart...
Failure) trial was designed to test the hypothesis that sacubitril/valsartan could result in reduced morbidity and mortality in patients with HFrEF in comparison to ACE-I therapy alone.[29] Inclusion criteria were NYHA functional class II–IV, LV ejection fraction, LVEF ≤40%, plasma BNP ≥150 pg/mL (or NT-proBNP ≥600 pg/mL), or a BNP ≥100 pg/mL (or NT-proBNP ≥400 pg/mL) if the patient was previously hospitalized for HF within the last 12 months. Further inclusion criteria at screening were estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m², systolic blood pressure ≥100 mmHg, and potassium ≤5.2 mmol/L. The primary endpoint was the composite of cardiovascular mortality or HF hospitalization; secondary endpoints included time to worsening of renal function and all-cause mortality.

The PARADIGM trial had a unique study design, with a single-blind active run-in period designed to assess the tolerability of both comparator study drugs. Once having completed the run-in phase, patients were randomly assigned to receive sacubitril/valsartan 200 mg b.i.d. or enalapril 10 mg b.i.d. in a double-blind fashion.

The trial finally enrolled 8442 patients in 47 countries from all over the world, thus qualifying as the largest study performed in patients with HFrEF so far. After a median follow-up of 27 months, the study was prematurely stopped according to the pre-specified regulations of the Data Monitoring Committee, as interim safety and efficacy data had indicated a significant

<table>
<thead>
<tr>
<th>Trial</th>
<th>Drug</th>
<th>Main inclusion criteria</th>
<th>Number of subject</th>
<th>Impact on primary end-points</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONSENSUS</td>
<td>Enalapril</td>
<td>Congestive HF, NYHA IV, cardiomegaly on chest X-ray</td>
<td>253</td>
<td>Reduction in all-cause mortality (40% at 6 months, p=0.002; 31% at 12 months, p=0.001)</td>
<td>CONSENSUS Trial Study Group, 1987[44]</td>
</tr>
<tr>
<td>SOLVD Treatment</td>
<td>Enalapril</td>
<td>LVEF ≤35%; NYHA I–IV (90% NYHA II–III)</td>
<td>2569</td>
<td>16% reduction in all-cause mortality (p=0.004), and 26% reduction in combined all-cause mortality and HF hospitalization rate (p&lt;0.0001)</td>
<td>SOLVD Investigators, 1991[45]</td>
</tr>
<tr>
<td>SOLVD Prevention</td>
<td>Enalapril</td>
<td>LVEF ≤35%; NYHA I–II</td>
<td>4228</td>
<td>8%, non significant, reduction in all-cause mortality (p=0.30); 29% risk reduction of the combined death and HF hospitalizations (p&lt;0.001)</td>
<td>SOLVD Investigators, 1992[46]</td>
</tr>
<tr>
<td>ATLAS</td>
<td>Lisinopril</td>
<td>LVEF ≤30%; NYHA II–IV</td>
<td>3164</td>
<td>Non significant reduction in all-cause mortality (8%, p=0.13) and in cardiovascular mortality (10%, p=0.07); 15% reduction in all-cause mortality or HF hospitalization rate (p=0.001)</td>
<td>Packer M et al, 1999[47]</td>
</tr>
<tr>
<td>ARBs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHARM-Added</td>
<td>Candesartan</td>
<td>LVEF ≤40%, NYHA II–IV, treatment with ACE-I</td>
<td>2548</td>
<td>15% reduction in rate of combined cardiovascular mortality or HF hospitalization (p=0.01)</td>
<td>McMurray JJV et al, 2003[48]</td>
</tr>
<tr>
<td>CHARM-Alternative</td>
<td>Candesartan</td>
<td>LVEF ≤40%, NYHA II–IV, intolerant to ACE-I</td>
<td>2028</td>
<td>23% reduction in rate of combined cardiovascular mortality or HF hospitalization rate (p=0.01)</td>
<td>Granger CB et al, 2003[49]</td>
</tr>
<tr>
<td>Val-HeFT</td>
<td>Valsartan</td>
<td>LVEF &lt;40%, NYHA II–IV, treatment with ACE-I, LVID &gt;2.9 cm/BSA</td>
<td>5010</td>
<td>Reduction in the combined endpoint of all-cause death, cardiac arrest with resuscitation, HF hospitalization, or i.v. administration of inotropes/vasodilators for ≥4 hours without hospitalization by 13% (p=0.009); no difference in all-cause mortality</td>
<td>Cohn JN et al, 2001[16]</td>
</tr>
</tbody>
</table>

Summary of major clinical trials testing the effects of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II type I receptor blockers (ARBs) in patients with heart failure and/or left ventricular dysfunction. BSA, body surface area; HF, heart failure; LVEF, left ventricular ejection fraction; LVID, left ventricular inner dimension; NYHA, New York Heart Association.

Figure 1. Schematic showing the mechanism of action of sacubitril/valsartan. The valsartan moiety blocks the angiotensin type I receptor; sacubitril is converted to the active natriuretic inhibitor LBO657, which inhibits neprilsin. ANP, atrial natriuretic peptide; AT1, angiotensin type I; BNP, B-type natriuretic peptide; CNP, C-type natriuretic peptide; NT-proBNP, N-terminal pro-BNP. Reprinted with permission from reference 28.
reduction in both the primary endpoint and in cardiovascular death. The final results demonstrated that sacubitril/valsartan reduced by 20% the relative risk of cardiovascular death or HF hospitalization compared to enalapril (hazard ratio, HR, 0.80; 95% CI: 0.73-0.87; p<0.0001). The analysis of the treatment effects on each single component of the primary endpoint was consistent with a significant reduction of the relative risk of either cardiovascular death (HR 0.80; IC 95% 0.71-0.89; p<0.0001) or HF hospitalizations (HR 0.79; IC 95% 0.71-0.89; p<0.0001) in the arm randomized to sacubitril/valsartan.[29] Finally, the secondary end-point of all-cause mortality was also reduced by 16% (HR 0.84; 95% CI 0.76, 0.93; p<0.0002). These findings were consistent across all pre-specified subgroups.

As concerns the safety profile, elevations in serum creatinine (≥2.5 mg/dl) or potassium (≥6 mmol/l), and cough were less common, whilst hypotension occurred more frequently in patients receiving sacubitril/valsartan. Of note, serious angioedema was rare and non-significant between treatment groups.

Sacubitril/valsartan in the heart failure therapeutic armamentarium

The results of PARADIGM-HF trial represent the most significant breakthrough in the management of HF of the last decade. For the first time after the successful introduction of drugs acting on neurohormonal activation, the conceptual framework in HF therapeutics has shifted from neurohormonal antagonism to neurohormonal modulation, with the combined blockade of detrimental effects of RAAS and the potentiation of the NP system.

A number of subsequent pieces of evidence have provided further insight into the benefits of sacubitril/valsartan in patients with HFrEF, for example as concerns quality of life assessed by the Kansas City Cardiomyopathy Questionnaire[30], the reduction in recurrent HF hospitalizations and/or cardiovascular death[31], and the early benefit in prevention of sudden cardiac death.[32] Following the overwhelming statistical evidence of efficacy, sacubitril/valsartan was given regulatory approval for use in patients who conform to the main inclusion criteria of the trial. [33,34] Also, the latest guidelines of ESC and of the American College of Cardiology (ACC) have both acknowledged a Class I, level of evidence B recommendation for sacubitril/valsartan to reduce the risk of HF hospitalisation and death in HFrEF patients who remain symptomatic despite treatment with an ACE-I or ARB, a beta-blocker and MRA, albeit providing the patients would have satisfied the inclusion and exclusion criteria of the PARADIGM-HF trial.[15,35]

There is more limited evidence supporting the use of sacubitril/valsartan as a first line therapy in patients with HFrEF who are ACE/ARB naïve, although a few were enrolled in the TITRATION trial (a study examining two initiation and up-titration regimens for sacubitril/valsartan) reporting equivalent rates of adverse events to the total population.[36] Furthermore, the safety and feasibility of initiation of sacubitril/valsartan in-hospital or shortly after discharge in patients with de novo or acutely decompensated HFrEF has been recently demonstrated by the TRANSITION trial.[37,38]

Clinical monitoring of patients receiving sacubitril/valsartan is also a matter of debate, as only BNP, but not NT-proBNP, is a substrate of NEP and may remain elevated or transiently increase following drug initiation. NT-proBNP measurement has therefore been suggested in the context of ARNI therapy when the estimation of an NP type biomarker is desired for patient follow-up.[39]

The future of combined RAAS/NEP inhibition

As neurohumoral deregulation represents one of the main pathophysiological determinants of the underlying mechanisms of LV remodelling and end-organ damage which are common to several cardiovascular diseases, sacubitril/valsartan has been tested in a number of large studies in clinical settings different from HFrEF, with two in particular of potentially major importance. The first is the PARAGON-HF trial, which showed no significant benefit of sacubitril/valsartan vs. valsartan in patients with HF and LVEF of 45% or higher.[40] The second is the PARADISE-MI, testing sacubitril/valsartan vs. ramipril in patients with LV systolic dysfunction and/or pulmonary congestion after acute myocardial infarction.[41] Finally, sacubitril/valsartan has been predicted to achieve an indication in patients at risk for developing HF, including those with arterial hypertension[42] and, possibly, in patients with chronic kidney disease, given the results of a post-hoc analysis of the PARADIGM-HF trial demonstrating a slower rate of decrease in the eGFR in patients randomized to receive ARNI.[43]

Declarations of interest

The authors declare no conflict of interest.

Acknowledgements

The authors state that they abide by the authors’ responsibilities and ethical publishing guidelines of the International Cardiovascular Forum Journal.[50]

References


